News | | More »

Interview with Lucia Masarova, Assistant Professor at MD Anderson Cancer Center

Equity research and Presentations

First patient dosed in the phase II study of tasquinimod in myelofibrosis in the US

Press Release

First patient enrolled in the HO172 clinical study of tasquinimod in myelofibrosis

Press Release

Active Biotech Year End Report 2024

Press Release

Positive preclinical tasquinimod data in myelofibrosis presented at ASH 2024 now available on Active Biotech’s website

Press Release

Infocus interview with CEO Helen Tuvesson at Redeye Technology & Life Science Day 2024

Equity research and Presentations

Active Biotech raises SEK 43.4 million in substantially oversubscribed rights issue including exercise of over-allotment option

Press Release

Active Biotech’s patent for laquinimod in eye disorders will be granted in the US

Press Release

Preclinical data of tasquinimod in myelofibrosis to be presented at ASH 2024

Press Release

Active Biotech’s clinical trial of tasquinimod in myelofibrosis approved in Europe

Press Release

Aktiespararna: Active Biotech: Sikte på avtal nästa år (in Swedish)

Equity research and Presentations

European Patent Office has granted Active Biotech’s patent application for eye drop formulation of laquinimod

Press Release

Active Biotech Interim Report Q3 2024

Press Release

Active Biotech reports intriguing intraocular concentrations achieved in a clinical biodistribution study of laquinimod eye drops

Press Release

Active Biotech enters agreement for a clinical study of tasquinimod in myelofibrosis

Press Release

Nasdaq Stockholm
ACTI
Financial Reports
Analyses and Presentations

Investor Relations

Tasquinimod
Laquinimod
Naptumomab

Projects

Annual Summary (in swedish)

We Develop New Treatments for Cancer and Inflammatory Diseases

We leverage our extensive knowledge and previously generated documentation on our assets to develop novel treatments for specialist indications with high medical need and commercial value within cancer and inflammatory eye disorders. We have a stringent focus on our projects in hematological cancers, non-infectious uveitis and in solid tumors for naptumomab in partnership with NeoTX.

Novel treatments for specialist indications

Financial Calendar

Events

There are no upcoming events.

Pipeline

Fully owned projects

Disease Area
Discovery
Preclinical
Phase I
Phase II
Phase III
Partner
Hematological malignancies
Tasquinimod Multiple myeloma*
Tasquinimod Myelofibrosis
Tasquinimod Myelofibrosis**
Inflammatory eye disorders
Laquinimod eye drops, safety and tolerability
Laquinimod eye drops, ocular biodistribution
Study ongoing
* In an academic partnership with the Abramson Cancer Center, Philadelphia, University of Pennsylvania
** Patient recruitment ongoing

Licensed projects

Disease Area
Discovery
Preclinical
Phase I
Phase II
Phase III
Partner
Solid tumors
Naptumomab Combination with docetaxel in non-small cell lung cancer
Naptumomab Combination with anti-PDL1 (durvalumab) in solid tumors

Our project portfolio comprises small, orally active immunomodulatory molecules as well as antibody-based immunotherapy. We have three projects in our project portfolio, Tasquinimod, Laquinimod and Naptumomab. Read more about Active Biotechs projects »

Uveitis can Lead to Severe Eye Problems Including Blindness

Laquinimod

Multiple Myeloma a Blood Cancer with Unmet Medical Need

Tasquinimod